Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric α-defensins in IBD Patients.

Related Articles Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric α-defensins in IBD Patients. J Clin Gastroenterol. 2019 Aug 09;: Authors: Deng Q, Tan G, Deng F, Zhi F Abstract BACKGROUND AND AIMS: Human enteric antimicrobial peptides composed predominantly of human enteric α-defensins (HD5 and HD6) are important in the mucosal antimicrobial barrier. Previous studies have identified that genetic variations at rs2066844, rs2066845, rs2066847 are associated with diminished enteric α-defensins in ileal Crohn’s disease (CD). However, genetic variations associated with enteric antimicrobial peptides in colonic…

Read More

Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.

Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis. J Clin Gastroenterol. 2019 Aug 01;: Authors: Antonelli E, Torti G, Bassotti G Abstract BACKGROUND: The treatment of ulcerative colitis (UC) is based on conventional therapies (aminosalicylates, corticosteroids, and immunosuppressants) and when these are ineffective, biologic drugs. However, in a substantial portion of patients undergoing treatment with biologic agents there is primary or secondary loss of response. Thus, new therapeutic options are been actively explored; among these, there is interest in the Janus kinase (JAK) inhibitors, small…

Read More

Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial.

Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial. J Clin Gastroenterol. 2019 Jul 26;: Authors: Ahamed Z R, Dutta U, Sharma V, Prasad KK, Popli P, Kalsi D, Vaishnavi C, Arora S, Kochhar R Abstract INTRODUCTION: Vitamin D possesses anti-inflammatory properties and could be beneficial in ulcerative colitis (UC). METHODS: We studied the effect of oral nano vitamin D3 supplementation on disease activity in active UC [ulcerative colitis disease activity index (UCDAI)≥3]. Patients with active UC and vitamin D <40 ng/mL…

Read More

Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy: A Systematic Review.

Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy: A Systematic Review. J Clin Gastroenterol. 2019 Jul 12;: Authors: Tandon P, Leung K, Yusuf A, Huang VW Abstract Active inflammatory bowel disease (IBD) may increase the risk of adverse outcomes during pregnancy. Our aim was to systematically review the role of noninvasive fecal tests, such as fecal calprotectin (FCP) and lactoferrin (FL), and laboratory tests including C-reactive protein (CRP), hemoglobin, and albumin in the assessment of IBD during pregnancy. A systematic search of electronic databases was performed through October…

Read More

Race/Ethnicity-specific Disparities in In-Hospital Mortality and Hospital Charges Among Inflammatory Bowel Disease-related Hospitalizations in the United States.

Race/Ethnicity-specific Disparities in In-Hospital Mortality and Hospital Charges Among Inflammatory Bowel Disease-related Hospitalizations in the United States. J Clin Gastroenterol. 2019 Apr 17;: Authors: Galoosian A, Rezapour M, Liu B, Bhuket T, Wong RJ Abstract GOAL: The goal of this study was to evaluate disparities in hospital outcomes among inflammatory bowel disease (IBD) related hospitalizations in the United States with a focus on ethnicity-specific disparities. BACKGROUND: IBD-related hospitalizations contribute to significant morbidity and health care economic burden. METHODS: IBD-related hospitalizations (identified with ICD-9) among US adults were evaluated using 2007…

Read More

Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis.

Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 Apr 15;: Authors: Dai C, Jiang M, Sun MJ, Cao Q Abstract OBJECTIVE: Persistent disease activity is associated with a poor prognosis in inflammatory bowel disease (IBD) patients. Therefore, monitoring of IBD activity can avoid the poor prognosis. Serum biomarkers reflect a summation of systemic host responses rather than being specific for intestinal inflammation. And endoscopic monitoring is invasive, costly, and time consuming. The objective of our study was to perform a…

Read More

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Mar 13;: Authors: Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW Abstract BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI). Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear. METHODS: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via…

Read More

Thirty Years of Lactobacillus rhamnosus GG: A Review.

Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41 Authors: Capurso L Abstract Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its ability to survive and to proliferate at gastric acid pH and in medium containing bile, and to adhere to enterocytes. Furthermore LGG is able to produces both a biofilm that can mechanically protect the mucosa, and different soluble factors beneficial to the gut by enhancing intestinal crypt survival, diminishing apoptosis…

Read More

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD.

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD. J Clin Gastroenterol. 2018 Nov 14;: Authors: Yadav A, Vasquez P, Dolgin NH, Falchuk KR, Feuerstein JD Abstract BACKGROUND: The American Gastroenterological Association (AGA) published guidelines on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) in August 2017 recommending use of reactive TDM to guide treatment changes in patients with active IBD who are being treated with anti-tumor necrosis factor (anti-TNF) agents or thiopurines. We sought to determine if changes in national clinical…

Read More
<< Go Back